Drug firm BDR Pharma on Wednesday said it has inked a licensing pact with Eli Lilly and Company for the manufacturing and distribution of Baricitinib for the treatment of COVID-19 in India. The company said it has entered into a royalty-free, limited and non-exclusive voluntary licensing agreement with Eli Lilly and Company. Baricitinib has received restricted emergency use approval, for use in combination with Remdesivir, for treatment of suspected or laboratory confirmed COVID-19 in hospitalised adults and pediatric patients two years of age or older, requiring supplemental oxygen, invasive mechanical ventilation, or extracorporeal membrane oxygenation.
Eli Lilly has received the permission for the drug for restricted emergency use from Central Drugs Standard Control Organization, a division of the Ministry of Health.
Read more about Natco Pharma signs licensing agreement with Eli Lilly on Business Standard. For manufacture and commercialization of Covid-19 drug - Baricitinib
Read more about Eli Lilly inks pact with Natco Pharma for Covid-19 drug baricitinib on Business Standard. Drug firm Eli Lilly said it has signed a voluntary licensing agreement with Natco Pharma to further expedite the availability of baricitinib for Covid-19 patients in India